A Phase IIb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Relapsed Small Cell Lung Cancer

Trial Profile

A Phase IIb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Relapsed Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs Belotecan (Primary) ; Topotecan (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Chong Kun Dang
  • Most Recent Events

    • 15 Sep 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
    • 15 Sep 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
    • 06 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2015 to 1 Feb 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top